ProPharma

Overview

ProPharma is a service-led, outsourced operating partner across regulatory sciences, pharmacovigilance, quality and compliance, medical information, clinical research, and R&D technology. It is best evaluated as an extension-of-team partner for launch-stage and mid-size biopharma rather than as a niche regulatory consultancy. ProPharma has been Odyssey Investment Partners-backed since September 2020; the post-2021 footprint reflects a deliberate roll-up that absorbed The Planet Group (May 2021), iSafety Systems (2021), Kateric (September 2022), Digital Lab Consulting (early 2023), and Diamond Pharma Services. ProPharma reports 2,500+ professionals across 27 offices on six continents.

ProPharma is not a CRO with large-scale Phase II/III clinical operations like ICON or Parexel, not a regulatory law firm, and not a niche regulatory affairs boutique. It belongs on the shortlist when the manufacturer needs broad lifecycle coverage across regulatory, PV, quality, MI, and clinical workflows from one vendor under coordinated governance.

Regulatory Compliance Capability Model

The framework below standardizes how Rx Almanac evaluates regulatory-compliance capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, ProPharma is evaluated as an extension-of-team partner for launch-stage and mid-size biopharma rather than as a niche regulatory consultancy.

Capability	Buyer should compare	ProPharma readout
Regulatory strategy and submissions	Submission planning, agency interactions, labeling strategy, variations, lifecycle management, and global filing support.	Core regulatory support. Regulatory sciences is a primary practice area; 2024 CPHI Regulatory and Compliance Award; Diamond Pharma Services acquisition added UK and EU regulatory depth.
Pharmacovigilance and safety operations	ICSR intake, case processing, signal detection, aggregate reports, REMS/safety support, and safety databases.	Core pharmacovigilance and safety. Pharmacovigilance is a primary practice area; 2021 iSafety Systems acquisition added PV technology and safety database capacity.
Quality systems and compliance auditing	GxP quality systems, SOPs, audits, inspection readiness, CAPA, vendor oversight, and training.	Core governance control. Quality and compliance is a primary practice area with inspection readiness, audit, and CAPA scope.
Labeling, promotional review, and medical/legal support	Label operations, MLR review, promotional compliance, medical information, and claims substantiation.	Regulatory support. Medical information sits inside the regulatory practice; confirm MLR workflow depth and integration with the manufacturer’s promotional review process.
Licensing, accreditation, and specialized counsel	Pharmacy, PBM, state licensing, accreditation, healthcare law, and niche regulatory counsel.	Confirm licensing workflow in the RFP. ProPharma is a regulatory services provider, not a law firm; pair with healthcare counsel for licensing, PBM, and state-law-specific scope.
Technology, workflow, and reporting infrastructure	Validated systems, regulatory information management, safety platforms, dashboards, and workflow automation.	Reporting layer. Digital Lab Consulting acquisition added scientific-informatics capabilities; confirm which specific RIM, safety, and quality platforms are validated and in production.

Buyer Fit

• When it belongs in the set: Launch-stage and mid-size biopharma needing one outsourced operating partner across regulatory, PV, quality, MI, and clinical workflows under coordinated governance.
• Best-fit buyers: Emerging biotech and mid-size pharma with multiple regulatory and safety workstreams but limited internal capacity; manufacturers that want broad coverage rather than separately contracting six niche vendors.
• Less ideal fit: Large pharma with mature in-house regulatory and PV functions; manufacturers needing a specialized regulatory law firm or a focused niche consultancy for one regulatory question.
• Commercial fit: Custom/RFP scoping; PE ownership means continuity and team-retention plans should be a diligence item.
• Operating diligence: Jurisdiction coverage, named accountable experts, validated systems, PV depth and ICSR throughput, where regulatory services end and legal advice begins, and how the Diamond, iSafety, Kateric, and Digital Lab Consulting acquired teams are integrated into one operating cadence.

Differentiators

• Broad lifecycle coverage across regulatory, PV, quality, MI, and clinical: One vendor across the regulated-services stack, useful when a launch-stage biopharma cannot staff six separate niche vendors.
• PE-backed roll-up depth: Planet Group, iSafety Systems, Kateric, Digital Lab Consulting, and Diamond Pharma Services acquisitions expanded human capital, PV technology, medical writing, scientific informatics, and EU/UK regulatory capacity.
• Global footprint: 2,500+ professionals across 27 offices on six continents support multi-jurisdiction regulatory and PV programs.
• Industry recognition: 2024 CPHI Regulatory and Compliance Award provides a third-party signal alongside the company’s own marketing claims.
• Extension-of-team operating model: Designed for buyers who want an integrated outsourced operating partner rather than transactional project consulting.

RFP Questions

• Which named experts will own regulatory strategy, PV operations, quality systems, and medical information for the specific program?
• Which validated systems (RIM, safety database, quality, MI, clinical) are in production, and how are audit trails, SOPs, CAPA, and inspection readiness maintained?
• How does ProPharma coordinate regulatory, PV, quality, MI, and promotional review workflows under one governance model?
• Which responsibilities does the engagement require separate healthcare counsel, local-country affiliates, or specialized technology licenses?
• How are the acquired Planet Group, iSafety, Kateric, Digital Lab Consulting, and Diamond Pharma Services teams integrated into one operating cadence?
• What turnover protections, named-team commitments, and continuity assurances apply across the current PE ownership cycle?
• Which jurisdictions does ProPharma cover directly versus through partner affiliates for global submissions and PV?

Recent Activity

• 2026-05 - Current ProPharma materials reinforce regulatory sciences, pharmacovigilance, quality, medical information, clinical, technology, and global outsourced operating-partner breadth.

• 2024-10: Received the CPHI Regulatory and Compliance Award.

• 2023-04: Opened a new global headquarters in Raleigh, NC (Research Triangle Park); the announcement described ProPharma as an Odyssey portfolio company.

• 2023-Q1: Acquired Digital Lab Consulting (UK), accelerating digital transformation and scientific-informatics capabilities.

• 2022-09: Acquired Kateric, adding global medical writing and clinical-trial-disclosure resources.

• 2021-05: Merged with The Planet Group, scaling human capital and specialized consulting divisions.

• 2021: Acquired iSafety Systems, expanding pharmacovigilance technology and safety database capacity.

• 2020-09: Odyssey Investment Partners acquired majority stake from Linden Capital Partners.